We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+13.27%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.42B
AUM Growth
-$150M
Cap. Flow
-$442M
Cap. Flow %
-12.92%
Top 10 Hldgs %
65.01%
Holding
63
New
3
Increased
6
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
FDMT icon
4D Molecular Therapeutics
FDMT
+$57.4M
2
XNCR icon
Xencor
XNCR
+$16M
3
AVTX icon
Avalo Therapeutics
AVTX
+$9.97M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$9.39M
5
AXSM icon
Axsome Therapeutics
AXSM
+$7.94M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$109M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$80.7M
3
MRUS
Merus
MRUS
+$75.7M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$59.4M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$51.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNX icon
26
Annexon
ANNX
$834M
$41.4M 1.21%
7,000,000
– –
CGON icon
27
CG Oncology
CGON
$6.2B
$37.5M 1.1%
994,596
-1,423,289
-59% -$49.9M
RPTX
28
DELISTED
Repare Therapeutics
RPTX
$35.5M 1.04%
10,333,600
– –
NAMS icon
29
NewAmsterdam Pharma
NAMS
$3.23B
$25.3M 0.74%
1,521,948
– –
XNCR icon
30
Xencor
XNCR
$1.51B
$17.1M 0.5%
+850,000
New +$16M
ELDN icon
31
Eledon Pharmaceuticals
ELDN
$259M
$15.7M 0.46%
6,293,282
– –
TCRX icon
32
TScan Therapeutics
TCRX
$48.4M
$14.9M 0.44%
2,989,474
– –
ENGN icon
33
enGene Therapeutics
ENGN
$116M
$14.9M 0.43%
2,251,037
– –
IMUX icon
34
Immunic
IMUX
$190M
$14.7M 0.43%
890,297
– –
ALLK
35
DELISTED
Allakos
ALLK
$10.8M 0.32%
16,552,417
– –
AVTX icon
36
Avalo Therapeutics
AVTX
$991M
$9.15M 0.27%
+967,000
New +$9.97M
IMA
37
ImageneBio Inc
IMA
$63.6M
$8.25M 0.24%
397,430
– –
CDTX
38
DELISTED
Cidara Therapeutics
CDTX
$7.56M 0.22%
703,065
+360,010
+105% +$4.32M
CTMX icon
39
CytomX Therapeutics
CTMX
$686M
$6.17M 0.18%
5,228,461
– –
VIGL
40
DELISTED
Vigil Neuroscience
VIGL
$6.17M 0.18%
1,813,633
– –
VTGN icon
41
VistaGen Therapeutics
VTGN
$9.78M
$6.02M 0.18%
2,000,000
– –
VSTM icon
42
Verastem
VSTM
$496M
$5.04M 0.15%
1,685,219
– –
OVID icon
43
Ovid Therapeutics
OVID
$418M
$4.55M 0.13%
3,853,818
– –
PVLA
44
Palvella Therapeutics
PVLA
$2.04B
$4.31M 0.13%
257,626
– –
VERV
45
DELISTED
Verve Therapeutics
VERV
$3.15M 0.09%
650,000
– –
SABS icon
46
SAB Biotherapeutics
SABS
$263M
$2.48M 0.07%
917,826
– –
MOLN
47
Molecular Partners
MOLN
$2.14M 0.06%
443,221
– –
ELEV
48
DELISTED
Elevation Oncology
ELEV
$1.78M 0.05%
2,966,836
+654,636
+28% +$971K
CBIO
49
Crescent Biopharma
CBIO
$523M
$1.61M 0.05%
95,443
– –
IVA
50
Inventiva
IVA
$1.04B
$1.27M 0.04%
686,040
– –
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2024 Portfolio in Review

As of Q3 2024, BVF Inc held 63 positions worth $3.42B, down 4.2% from $3.57B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

BVF Inc withdrew a net $442M in Q3 2024, closing 8 positions and reducing 10 holdings. Its most notable exit was Merus, an estimated $75.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in Xencor worth $17.1M.

  • BVF Inc's largest Q3 2024 buy was Xencor: 850,000 shares worth $17.1M.
  • BVF Inc added most to 4D Molecular Therapeutics in Q3 2024, an estimated $57.4M increase.
  • BVF Inc's biggest Q3 2024 reduction was Revolution Medicines, cutting an estimated $109M.
  • BVF Inc fully exited Merus in Q3 2024, selling an estimated $75.7M.
  • BVF Inc's ten largest holdings make up 65% of its $3.42B portfolio in Q3 2024.
  • BVF Inc opened 3 new positions and closed 8 in Q3 2024.
  • BVF Inc's portfolio value fell 4.2% quarter-over-quarter to $3.42B.

Based on BVF Inc's 13F filing for Q3 2024, filed 14 Nov 2024.